This technology is a broadly neutralizing antibody against all tested SARS-CoV-2 variants of concern and related sarbecoviruses for therapeutic neutralization of SARS-CoV-2 in infected patients.
Though effective for the general public, current prophylactic vaccination methods for respiratory viruses, such as SARS-CoV-2, fail to provoke a durable antiviral immune response in patients who are immunocompromised. Therefore, these patients rely on the efficacy of antibody therapeutics to achieve robust neutralization and clearance of virus. However, variants of SARS-CoV-2 arise that can be resistant to existing antibody therapies, leaving minimal options for immunocompromised patients. Therefore, there is a need for antibody treatments that have wide inhibitory activity and can be easily modified to target novel strains.
This technology is an engineered antibody that has broadly neutralizing potential against SARS-CoV-2 variants and several related sarbecoviruses. This technology isolates an antibody targeting the SARS-CoV-2 spike protein that effectively neutralizes all SARS-CoV-2 variants of concern and is further optimized to enhance its neutralizing potency and breadth. It also demonstrated promising neutralizing activity against SARS-CoV-2-like sarbecoviruses and clade 2 sarbecoviruses. As such, this therapeutic antibody could be utilized to decrease the severity of SARS-CoV-2 infection in patients and can potentially be used to treat future outbreaks caused by emerging variants and related sarbecoviruses.
Patent Pending
IR CU24218
Licensing Contact: Kristin Neuman